What is VIP?
Vasoactive intestinal peptide, VIP, is a signaling molecule your body already makes. Named for its first-discovered effects on the gut and blood vessels, it turned out to be something bigger: a messenger running between the nervous system and the immune system, carrying calm in both directions.
Because the body produces it naturally, the therapeutic question is specific: where does VIP signaling fall short, and where might adding more settle an overactive inflammatory state? A synthetic form, aviptadil, has carried that question into real clinical trials, which gives VIP a firmer human record than most peptides in this territory.
How does it work?
Immunologically, VIP is an anti-inflammatory, immunoregulatory signal: it shifts immune activity away from a pro-inflammatory state toward balance, influencing which cells activate and which messengers they release, a picture built on a substantial mechanistic literature.
It also relaxes smooth muscle and dilates blood vessels and airways, which is why the clinical research concentrated on the lungs, an organ that is simultaneously vascular, muscular, and immune-exposed. Both mechanisms describe how VIP acts in laboratory and early human work rather than proving outcomes in any given condition, and the trials below are where the mechanism met reality.
Why it matters
Runaway inflammation with tissue damage is the common enemy across half of serious medicine, and most tools against it are blunt. A natural signal that calms immunity while relaxing airways drew researchers to the hardest possible test, critical COVID-19 respiratory failure, and to chronic inflammatory lung disease. For the broader wellness conversation, VIP's value is mostly as a lesson in condition-specific evidence: its real trials are in defined lung diseases, not general health.
What the trials showed
The most controlled evidence is a 2022 randomized controlled trial in Critical Care Medicine: intravenous aviptadil in 196 patients with critical COVID-19 respiratory failure, followed 60 days (registered as NCT04311697). Its primary endpoint, alive and free of respiratory failure at day 60, did not reach statistical significance; the investigators reported roughly two-fold improved odds of survival at day 60 and reduced interleukin-6 by day 3. A miss on the primary with suggestive secondaries, in the sickest patients imaginable.
The clearest immune demonstration came earlier: a 2010 phase 2 trial of inhaled VIP in 20 sarcoidosis patients, where nebulized VIP was well tolerated, cut production of the inflammatory cytokine TNF-alpha, and increased regulatory T cells, the first human demonstration of VIP's immunoregulatory effect. A longer-acting analogue, pemziviptadil, has been carried into pulmonary arterial hypertension trials (NCT03556020), keeping the program alive.
What people notice in practice
VIP appears in practice mainly in two niches: nasal spray protocols aimed at inflammatory conditions, including the mold-illness and CIRS community, and combination peptide protocols (SCR's own catalog pairs it with MOTS-c). What users report, labeled honestly as experience rather than trial evidence, is gradual: clearer breathing, less inflammatory fog, steadier energy over weeks. The nasal-spray route and the wellness populations using it sit entirely outside the trial evidence, which studied IV and nebulized forms in defined lung disease.
The pros and the cons
What's promising
- A natural signal with a substantial immunoregulation literature behind it.
- Real randomized-trial evidence, rare in this territory: 196 patients in critical care.
- A demonstrated human immune effect: lower TNF-alpha, more regulatory T cells in sarcoidosis.
- An active development program through longer-acting analogues.
What's uncertain
- The flagship trial missed its primary endpoint; the survival signal was secondary.
- The evidence is condition-specific to serious lung disease, not general wellness.
- The nasal-spray practice route has no controlled evidence at all.
- No VIP product is approved for any use.
Worth considering
- VIP is a systemic vasodilator by nature; blood-pressure effects are part of its biology.
- Serious respiratory or inflammatory disease belongs in specialist care, full stop.
- Practice use runs on routes and populations the trials never touched.
- Sourcing and physician oversight, as everywhere in this library.
Why the evidence looks the way it does
VIP got its human trials for the classic reason: sponsors existed when specific diseases, COVID respiratory failure and pulmonary hypertension, offered approvable indications for synthetic forms. The wellness uses never had that engine, so they run on mechanism and anecdote while the real data stays condition-specific. Reading VIP honestly means letting the lung trials be lung trials rather than a general endorsement.
What the key trials tested
Our framing rule for evidence: a trial tests one form, one route, one population, one endpoint. Where the evidence sits:
Preclinical & practice
The immunoregulation literature, and all nasal-spray and wellness use.
Early trials
Inhaled VIP in sarcoidosis (20 patients): the first human immunoregulatory demonstration.
Late-stage trials
IV aviptadil in critical COVID-19 (196 patients, randomized); pemziviptadil in pulmonary hypertension.
Approved uses
None, anywhere.
Every study behind this article is filterable in our research library on the Science page.
Questions people ask
What does VIP actually do in the body?
Two jobs at once: it signals immune cells toward a calmer, more regulated state, and it relaxes smooth muscle, dilating blood vessels and airways. The body uses it as a messenger between the nervous and immune systems, which is why researchers tested adding more of it where inflammation runs hot in the lungs.
Did the COVID trial work?
Strictly, no: the primary endpoint, alive and free of respiratory failure at day 60, did not reach significance in 196 critical patients. Suggestively, maybe: the investigators reported about two-fold improved survival odds and a drop in the inflammatory marker IL-6. That mix, primary missed with encouraging secondaries, is exactly the kind of result that keeps a compound in development without proving it.
What about VIP nasal spray?
It is the most common practice form, popular in inflammatory-illness communities, and it has no controlled evidence: the trials used intravenous and nebulized routes in defined lung diseases. The spray inherits the mechanism story, not the trial results. Anyone using it should know exactly that, and serious respiratory disease belongs with specialists regardless.
Is VIP safe?
The trials reported reasonable tolerability, including in critically ill patients, with the caveat that VIP is a vasodilator by nature, so blood-pressure effects are inherent to its biology. Outside trial settings, the usual questions apply: unapproved product, gray-market sourcing, and routes nobody has formally studied.
What to take away
If you remember five things from this article, make them these:
- VIP is the body's own nerve-to-immune calming messenger, with real mechanistic depth behind it.
- It has genuine randomized-trial evidence, and that evidence is specific to serious lung disease.
- The flagship COVID trial missed its primary endpoint while hinting at survival benefit.
- The sarcoidosis trial delivered the cleanest result: a demonstrated human immune-calming effect.
- Nasal-spray wellness use rides the mechanism, not the trials, and honest expectations follow from that.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. VIP is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.